Abcam, ab120320, GS 39783, GABAB positive allosteric modulator

Size: 10mg / 50mg
MW 337.4 Da, Purity >99%. Novel, GABAB positive allosteric modulator (EC50 = 3 μM for [35S]GTPγS binding). Shows anxiolytic and antiaddictive effects *in vivo.* Blood-brain barrier permeable*.* Orally active.
Key facts
CAS number:39069-52-8,
Purity:>99%,
Form:SolidSee storage information,
Molecular weight:337.4 Da,
Molecular formula:C15H23N5O2S,
PubChem:6604928,
Nature:Synthetic,
Solubility:Soluble in DMSO to 25 mM,
Biochemical name:N4,N6-dicyclopentyl-2-(methylthio)-5-nitropyrimidine-4,6-diamine,
Biological description:Novel, GABAB positive allosteric modulator (EC50 = 3 μM for [35S]GTPγS binding). Shows anxiolytic and antiaddictive effects *in vivo.* Blood-brain barrier permeable*.* Orally active.,
Canonical smiles:CSC1=NC(=C(C(=N1)NC2CCCC2)[N+](=O)[O-])NC3CCCC3,
InChi:InChI=1S/C15H23N5O2S/c1-23-15-18-13(16-10-6-2-3-7-10)12(20(21)22)14(19-15)17-11-8-4-5-9-11/h10-11H,2-9H2,1H3,(H2,16,17,18,19),
InChiKey:GSGVDKOCBKBMGG-UHFFFAOYSA-N,
IUPAC Name:4-N,6-N-dicyclopentyl-2-methylsulfanyl-5-nitropyrimidine-4,6-diamine

Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Store in the dark, Store under desiccating conditions, This product is air and light sensitive and impurities can occur as a result of air oxidation or due to metabolism by microbes

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The CYP2C9 protein also known as Cytochrome P450 2C9 is an important enzyme in the liver responsible for metabolizing several drugs. This target exhibits a mass of approximately 55 kDa and is expressed mainly in hepatic tissues. It belongs to the cytochrome P450 superfamily which includes closely related isoforms such as CYP2C8 CYP2C19 and CYP2C12. These proteins play a collective role in drug metabolism and synthesis of cholesterol steroids and other lipids. Additionally the GABA B Receptor 2 (GABBR2) and GABA B Receptor 1 work together as part of the GABA B receptor system in the central nervous system to mediate neuronal inhibition through neurotransmitter modulation.
Biological function summary
CYP2C9 contributes to the oxidative metabolism of a wide range of exogenous substrates including about 15% of therapeutic drugs like anticoagulants antidiabetics and antiepileptics. The enzyme engages in complex formation within the endoplasmic reticulum of liver cells where it interacts with cytochrome P450 reductase and cytochrome b5 modulating its activity. In the context of the GABA B receptor complex GABBR2 pairs with GABBR1 to form a heterodimer exerting inhibitory neurotransmission via G-protein-coupled inwardly-rectifying potassium channels and reducing cellular excitability.
Pathways
CYP2C9 operates principally in the drug metabolism pathway which impacts pharmacokinetics and influences drug efficacy and safety. Its enzymatic activity governs the metabolism of drugs through hydroxylation processes sharing its functional relation with other cytochromes like CYP2C19. Meanwhile the GABA B receptor engages in the inhibitory neurotransmission pathway. As a positive allosteric modulator it interacts with other neurotransmitter systems such as glutamate to maintain central nervous system homeostasis.
CYP2C9 polymorphisms are frequently implicated in adverse drug reactions particularly affecting medication like warfarin due to its how individual metabolic variations can alter drug response. This enzyme shares associations with conditions like drug-induced hepatotoxicity involving the participation of related isoforms like CYP2C19. The GABA B receptors through their modulatory function relate significantly to neurological disorders such as epilepsy. Here their interaction with neurotransmitters and proteins like G-proteins which mediate signal transduction reflects their role in the progression and treatment of these conditions.